High-dose chemotherapy in metastatic breast cancer
Leonard, R.C.
Lancet 351(9107): 986
1998
ISSN/ISBN: 0140-6736 PMID: 9734966 Document Number: 484473
Document emailed within 1 workday
Related Documents
Bearman, S.I.; Shpall, E.J.; Jones, R.B.; Cagnoni, P.J.; Ross, M. 1996: High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer Seminars in Oncology 23(1 Suppl 2: 60-67Stemmler, H.J.; Salat, C.; Lindhofer, H.; Menzel, H.; Untch, M.; Kahlert, S.; Konecny, G.; Sauer, H.; Ledderose, G.; Heinemann, V.; Kolb, H.J. 2005: Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study Anticancer Research 25(4): 3047-3054
Chen, T.L.; Passos-Coelho, J.L.; Noe, D.A.; Kennedy, M.J.; Black, K.C.; Colvin, O.M.; Grochow, L.B. 1995: Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation Cancer Research 55(4): 810-816
Razis, E.D.; Samonis, G.; Cook, P.; Beer, M.; Mittelman, A.; Lake, D.E.; Feldman, E.J.; Puccio, C.; Ahmed, T. 1994: TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer Journal of Medicine 25(3-4): 241-250
Pannuti, F.; Di Marco, A.R.; Rossi, A.P.; Rocchetta, G.; Rubino, I.; Giovannini, M.; Fruet, F. 1981: Sequential hormone-chemotherapy (MAP at high doses and CMF) in metastatic breast cancer. Preliminary results Panminerva Medica 23(2): 93-96
Filip, S.; Petera, J.; Odrázka, K.; Bláha, M. 2000: The current look at high-dose chemotherapy in breast cancer minireview Neoplasma 47(5): 261-268
Meropol, N.J.; Overmoyer, B.A.; Stadtmauer, E.A. 1992: High-dose chemotherapy with autologous stem cell support for breast cancer Oncology 6(12): 53-60; 63; Discussion: 63-4 69
Toh, H.C. 2000: High dose chemotherapy in breast cancer--a thin red line between hype and hope Singapore Medical Journal 41(2): 86-88
Kennedy, M.J. 1997: Issues relating to the inclusion of high-dose chemotherapy in breast cancer treatment guidelines Oncology 11(11a): 121-126
Antimi, M. 1998: High-dose chemotherapy of breast cancer with hematopoietic protection; current status and prospectives La Clinica Terapeutica 149(921): 7-9
Kubota, O.; Onuki, Y.; Uchiyama, T.; Oishi, K.; Takeda, M. 2012: Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(5): 753-757
Mesía, R.; Solá, C.; López Pousa, A.; Mendoza, L.; Bellet, M.; Andrés, L.; López López, J.J. 1994: High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas Revista Clinica Espanola 194(11): 960-965
Rühl, U. 2000: Consolidation radiotherapy after high-dose chemotherapy and autologous bone marrow transplantation in patients with advanced breast cancer Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 176(4): 196-197
Ohtake, T.; Yasuda, M.; Watanabe, K.; Ito, T.; Ito, J.; Miyamoto, K.; Yoshida, S.; Abe, N.; Ishigame, T.; Ishii, M.; Kimijima, I.; Takenoshita, S. 2009: Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(9): 1459-1463
Koyama, H.; Iesato, A.; Fukushima, Y.; Okada, T.; Watanabe, T.; Harada, M.; Ito, T.; Maeno, K.; Mochizuki, Y.; Ito, K.; Amano, J. 2011: A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1123-1126
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Lucey, C.; Westphal, J.R. 1998: New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer Southern Medical Journal 91(2): 196-201
Tokuda, Y. 2000: High-dose chemotherapy for treatment of breast cancers Nihon Rinsho. Japanese Journal of Clinical Medicine 58 Suppl: 292-297
Tashiro, H. 2000: Standard chemotherapy for metastatic breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 58 Suppl: 246-253
Pacetti, U.; Veltri, E.; Fattoruso, S.Ileana.Sara.; Cardillo, F.D'Assisi.; Evangelista, S.; Cognetti, F.; Fabi, A. 2013: Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer Anticancer Research 33(4): 1721-1724